Fundraising FoxFirst In Ventures — 2023 Investments
2 investments dated 2023 · listed companies and verified rows first · show all
Baltimore-based immunology company focused on treatments for cancer and autoimmune disorders; raised an $11.5 million Series C led by First In Ventures.
BiotechBaltimore, US
David S. Block(Executive Officer, Director)Elizabeth C. Block(Executive Officer)Raymond Shinazi(Director)Joseph Klein(Director)Mark Lerner(Director)
BoardCharles Polsky(Director)
Board seatKyle Rusconi· per SEC Form D
Co-investorsBrace Pharma
N-able delivers unified cybersecurity and data protection solutions including endpoint management (N-central), AI-powered threat detection and response (Adlumin), and disaster recovery services (Cove).
AI & Machine LearningCloud ComputingCybersecurityEnterprise SoftwareAlexandria, US
Robert S. Jonhston(Executive Officer, Director)
Co-investorsBankTech VenturesJHH vcSyn Ventures Seed Management LlcWashington Harbour PartnersFirst InLeawood Venture Capital Llc
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.